Sign In
24 Dec 2010 07:00
24 December 2010
Cyprotex PLC
("Cyprotex" or "the Company")
Trading Update
Cyprotex PLC (LSE:CRX), the preclinical ADME Tox services company, announces that the Company has made solid progress following the integration of Apredica and Cellumen. The Directors expect full year results for the period ended 30 December 2010 to be in line with market expectations as described in the most recently published analyst note of 23 November 2010.
Dr Anthony D Baxter, Cyprotex's Chief Executive Officer, said:
"Following our acquisition of Apredica in August and the introduction of our new CellCiphr(TM) toxicology suite, we are pleased to report good, steady progress in trading. We expect our numbers to be in line with market expectations and our ongoing investment programme reflects our continued confidence in the future prospects for Cyprotex."
Enquiries:
Cyprotex PLC | Tel: +44 (0) 1625 505 100 |
Dr Anthony Baxter, Chief Executive Officer John Dootson, Chief Financial Officer Mark Warburton, Chief Operating Officer and Legal Counsel | |
ir@cyprotex.com | www.cyprotex.com |
Singer Capital Markets Limited (broker to Cyprotex) | Tel: +44 (0) 203 205 7500 |
Shaun Dobson shaun.dobson@singercm.com | |
Claes Spang | |
claes.spang@singercm.com | www.singerscm.com |
Financial Dynamics | Tel: +44 (0) 20 7831 3113 |
Ben Brewerton Ben Atwell Mo Noonan | |
cyprotex@fd.com | www.fd.com |
Notes to Editors:
Cyprotex PLC
Cyprotex is the world's largest contract research organisation (CRO) specialising in ADME Tox, which is the analysis of the Absorption, Distribution, Metabolism, Excretion and Toxicity properties of potential drugs, cosmetics, and agrochemicals. It is the only company in the world with in-house capabilities for both in vitro (test tube) and in silico (computer modelling) ADME Tox. Cyprotex was founded in 1999 and listed on the AIM in 2002. It has laboratories in Macclesfield, Cheshire, UK (near Manchester), and Watertown, Massachusetts, USA (near Boston), making it one of only three ADME Tox CROs with international operations.
www.cyprotex.com
Follow the stocks
